Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K

Citations Over TimeTop 11% of 2003 papers

Abstract

Osteoclast-mediated bone matrix resorption has been attributed to cathepsin K, a cysteine protease of the papain family that is abundantly and selectively expressed in osteoclast. Inhibition of cathepsin K could potentially be an effective method to prevent osteoporosis. Structure-activity studies on a series of reversible ketoamides based inhibitors of cathepsin K have led to identification of potent and selective compounds. Crystallographic studies have given insights into the mode of binding of these inhibitors. A series of ketoamides with varying P1 moieties were first synthesized to find an optimum group that would fit into the S1 subsite of the cysteine protease, cathepsin K. With a desired P1 group in place a variety of heterocyclic analogues in the P' region were synthesized to study their steric and electronic effects. In the process of exploring these P' heterocyclic variations, excellent selectivity was gained over other highly homologous cysteine proteases, including cathepsins L, S, and V. The favorable pharmacokinetic properties of some of these cathepsin K inhibitors in rats make them suitable for evaluation in rodent osteoporosis models. A representative cathepsin K inhibitor was shown to attenuate PTH-stimulated hypercalcemia in the TPTX rat model. These inhibitors provide a viable lead series in the discovery of new therapies for the prevention and treatment of osteoporosis

Related Papers

• → Regulation of HIV-1 Protease Activity through Cysteine Modification(1996)102 cited
• → Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K(2003)45 cited
• → Identification of EhICP1, a chagasin‐like cysteine protease inhibitor of Entamoeba histolytica(2005)43 cited
• → 3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity(2003)56 cited
• [Behavior of small molecular cysteine proteinase inhibitors in lung cancers and surrounding tissue].(1984)